非小细胞肺癌患者血清miR-195的表达及其临床意义

doi:10.11904/j.issn.1002-3070.2018.05.006

摘要/Abstract

摘要： 目的探讨血清miR-195在非小细胞肺癌(NSCLC)患者中的表达及其临床意义。方法采用实时荧光定量PCR(qRT-PCR)检测100例非小细胞肺癌患者和90例正常健康体检者血清miR-195的表达量,结合临床资料分析其表达在临床中的作用和意义。结果与正常人群相比,NSCLC患者血清miR-195相对表达量降低(7.26±1.61 vs. 4.52±1.17,P＜0.01);Ⅲ~Ⅳ期NSCLC患者血清miR-195相对表达量低于Ⅰ~Ⅱ期患者,有淋巴结转移的NSCLC患者血清miR-195相对表达量低于无淋巴结转移者,有远处转移的NSCLC患者血清miR-195相对表达量低于无淋巴结转移者,差异均有统计学意义(P＜0.05),而血清miR-195相对表达量在鳞癌和腺癌患者中无统计学差异,在高分化、中分化、低分化患者中也无统计学差异;Logistic回归分析结果显示,miR-195相对表达量(OR=0.526,95%CI:0.415~0.697,P=0.007)与NSCLC密切相关;血清miR-195相对表达量诊断NSCLC的AUC为0.875(95% CI:0.826~0.923,P=0.004);血清中高表达miR-195的NSCLC患者中位生存时间明显长于血清中低表达miR-195者(P＜0.05),多因素分析表明血清miR-195相对表达量是NSCLC预后的独立影响因素(HR=0.615,95%CI:0.324~0.783;P=0.011)。结论 NSCLC患者血清miR-195表达量降低,并且与NSCLC的分期、淋巴转移、远处转移和预后关系密切,血清miR-195有望成为NSCLC潜在的早期诊断、预后评价的分子标志物。

关键词: miR-195, 非小细胞肺癌, 血清

Abstract: Objective The aim of this study was to explore the expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer(NSCLC).Methods Real-time quantitative PCR(qRT-PCR)was used to detect the expression of serum miR-195 in 100 patients with NSCLC and 90 normal healthy subjects.The clinical significance and significance of its expression in clinical analysis were analyzed.Results Compared with the healthy control group(4.52±1.17),the relative expression of serum miR-195 was decreased in patients with NSCLC(7.26±1.61)(P＜0.01).The relative expression of serum miR-195 in patients with Ⅲ~Ⅳ phase of NSCLC was lower than that in patients with I-II phase of NSCLC.The relative expression of serum miR-195 in patients with lymph node metastasis was lower than that in patients without lymph node metastasis.The relative expression of serum miR-195 in patients with distant metastasis was lower than that in patients without lymph node metastasis.They showed a significant difference(P＜0.05).However,the relative expression of serum miR-195 was not statistically different in patients between squamous cell carcinoma and adenocarcinoma,and there was no statistical difference in highly differentiated,moderately differentiated,and poorly differentiated patients.Logistic regression analysis showed that serum miR-195 was significantly correlated with NSCLC(OR=0.526,95%CI:0.415~0.697,P=0.007).Area under ROC(AUC)of serum miR-195 was 0.875(95%CI:0.826~0.923,P=0.004)for the diagnosis of NSCLC.In addition,the NSCLC patients in the high miR-195 expression group was significantly longer the overall survival time than that of patients with low expression of miR-195 in serum(P＜0.05).Multivariate analysis showed that the serum miR-195 expression was an independent influence factor for NSCLC(HR=0.615,95%CI:0.324~0.783,P=0.011).Conclusion The expression of serum miR-195 is decreased in patients with NSCLC,and it is closely related to staging,lymphatic metastasis,distant metastasis and prognosis of NSCLC.Serum miR-195 is expected to be a molecular marker for potential early diagnosis and prognosis evaluation of NSCLC.

Key words: MiR-195, Non-small cell lung cancer, Serum

中图分类号:

R734.2

蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.

CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.

参考文献

1 Wink KC,Roelofs E,Solberg T,et al.Particle therapy for non-small cell lung tumors:where do we stand? A systematic review of the literature[J].Front Oncol,2014,4:292.
2 Bartel DP.MicroRNAs:Genomics,biogenesis,mechanism,and function[J].Cell,2004,116(2):281-297.
3 Ding X,Zhong T,Jiang L,et al.MiR-25 enhances cell migration and invasion in non-small-cell lung cancer cells via ERK signaling pathway by inhibiting KLF4[J].Mol Med Rep,2018,17(5):7005-7016.
4 Han L,Chen W,Xia Y,et al.MiR-101 inhibits the proliferation and metastasis of lung cancer by targeting zinc finger E-box binding homeobox 1[J].Am J Transl Res,2018,10(4):1172-1183.
5 Yu X,Zhang Y,Cavazos D,et al.miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer[J].Cell Death Dis,2018,9(2):193.
6 Lian J,Lin SH,Ye Y,et al.Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer[J].Oncotarget,2018,9(19):14895-14908.
7 孙彦珍,李珍,袁征.MircoRNA-195 在胃癌患者血清及组织中的表达水平及意义[J].中国现代医学杂志,2016,26(5):59-62.
8 Sun M,Song H,Wang S,et al.Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer[J].J Hematol Oncol,2017,10(1):79.
9 Chen Q,Wang C,Zhang H,et al.Expression levels of serum miR-195 in different types of patients with cholangiocarcinoma and its value to determine the prognosis thereof[J].Oncol Lett,2018,15(4):5947-5951.
10 Yan JJ,Chang Y,Zhang YN,et al.miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma[J].Oncol Lett,2017,13(5):3118-3126.
11 Duyu M,Durmaz B,Gunduz C,et al.Prospective evaluation of whole genome microRNA expression profiling in childhood acute lymphoblastic leukemia[J].Biomed Res Int,2014,2014:967585.
12 Liu B,Qu J,Xu F,et al.MiR-195 suppresses non-small cell lung cancer by targeting CHEK1[J].Oncotarget,2015,6(11):9445-9456.
13 Wang X,Wang Y,Lan H,et al.miR-195 inhibits the growth and metastasis of NSCLC cells by targeting IGF1R[J].Tumor Biol,2014,35(9):8765-8770.
14 Yu X,Zhang Y,Cavazos D,et al.miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer[J].Cell Death Dis,2018,9(2):193.
15 Zhang H,Su Y,Xu F,et al.Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers[J].PLoS One,2013,8(11):e81408.
16 Zhao Q,Cao J,Wu YC,et al.Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers[J].Am J Cancer Res,2015,5(5):1692-1705.
17 Landi MT,Zhao Y,Rotunno M,et al.MicroRNA expression differentiates histology and predicts survival of lung cancer[J].Clin Cancer Res,2010,16(2):430-441.

[1]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[2]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[3]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[4]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[5]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[6]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[7]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[8]	方杏华综述, 宋英审校. GOLPH2在恶性肿瘤中作用及机制的研究进展[J]. 实用肿瘤学杂志, 2017, 31(5): 458-462.
[9]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.
[10]	胡海峰, 冯谢敏, 乔健, 段伟, 刘宁宁, 孙晓东. miR-345在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(2): 117-122.
[11]	李恩就, 胡菂菂, 龚志军, 卿笃桔, 刘虹, 黎飞. 血清胃蛋白酶原联合Ca724在胃癌患者中的诊断及预后价值[J]. 实用肿瘤学杂志, 2017, 31(1): 18-22.
[12]	张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.
[13]	任凤海,王丹丹,王俊峰,徐海,徐世东. 单孔与单操作孔电视辅助胸腔镜手术治疗ⅠA期非小细胞肺癌的临床对比研究[J]. 实用肿瘤学杂志, 2016, 30(4): 327-331.
[14]	叶磊光, 闫安, 刘宝刚. Aurora-A参与非小细胞肺癌化疗药耐药与患者预后的关系[J]. 实用肿瘤学杂志, 2016, 30(2): 97-102.
[15]	陈明慧, 陈喜杰综述, 王艳审校. CD44v6与非小细胞肺癌的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 172-175.